This study will adapt and scale existing AHRQ-supported interoperable CDS for patient-centered chronic pain care. The objective of this project is to study the adaptation and implementation of an existing interoperable CDS tool for pain treatment shared decision making, with tailored implementation support, in primary care clinical settings. The central hypothesis is that tailored implementation support will increase CDS adoption and shared decision making.
This study will adapt and scale the use of existing AHRQ-supported interoperable CDS that aids patient-centered chronic pain treatment decision making. The research will generate critical evidence on scalable strategies to implement and evaluate interoperable CDS in real-world settings across different types of EHRs. The pragmatic trial will enhance the reach of interoperable CDS to more diverse populations. Together, these efforts will lead to important new technology and evidence that patients, clinicians, and health systems can use to improve care for millions of Americans who suffer from pain and other chronic conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
39
Individualized training, technical assistance, and workflow assessments.
UF Health Family Medicine - Commonwealth
Jacksonville, Florida, United States
Adoption
Rate of qualifying patients seen for whom CDS use is documented
Time frame: During the implementation trial (5 months total)
Reach
Rate of clinic encounters where CDS is documented
Time frame: During the implementation trial (5 months total)
Shared decision making
SDM-Q-9 questionnaire: 9-item Shared Decision Making Questionnaire
Time frame: Immediately after the intervention
Pain and function
PEG-3: 3-item scale that measures pain on average, its interference with enjoyment of life, and with general activity
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Any opioid prescription
Binary measure of treatment choice that increases opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Opioid prescriptions ≥50 MME/day
Binary measure of treatment choice that increases opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Opioid prescriptions ≥90 MME/day
Binary measure of treatment choice that increases opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Benzodiazepine prescription concurrent with opioid prescription
Binary measure of treatment choice that increases opioid-related risks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Prescriptions for non-opioid pain medications
Binary measure recommended by the CDC to decrease opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Prescriptions for non-pharmacologic pain treatments
Binary measure recommended by the CDC to decrease opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Urine drug screen orders
Binary measure recommended by the CDC to decrease opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Naloxone prescriptions
Binary measure recommended by the CDC to decrease opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months
Prescription or referral for medication-assisted therapy (MAT)
Binary measure recommended by the CDC to decrease opioid-related risks
Time frame: Baseline/pre-intervention, and at 1 and 3 months